Search Results - "Sauter, J.L."

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) by Cottrell, T.R., Thompson, E.D., Forde, P.M., Stein, J.E., Duffield, A.S., Anagnostou, V., Rekhtman, N., Anders, R.A., Cuda, J.D., Illei, P.B., Gabrielson, E., Askin, F.B., Niknafs, N., Smith, K.N., Velez, M.J., Sauter, J.L., Isbell, J.M., Jones, D.R., Battafarano, R.J., Yang, S.C., Danilova, L., Wolchok, J.D., Topalian, S.L., Velculescu, V.E., Pardoll, D.M., Brahmer, J.R., Hellmann, M.D., Chaft, J.E., Cimino-Mathews, A., Taube, J.M.

“…Neoadjuvant anti-PD-1 may improve outcomes for patients with resectable NSCLC and provides a critical window for examining pathologic features associated with…”
Get full text

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas by Schoenfeld, A.J., Rizvi, H., Bandlamudi, C., Sauter, J.L., Travis, W.D., Rekhtman, N., Plodkowski, A.J., Perez-Johnston, R., Sawan, P., Beras, A., Egger, J.V., Ladanyi, M., Arbour, K.C., Rudin, C.M., Riely, G.J., Taylor, B.S., Donoghue, M.T.A., Hellmann, M.D.

“…Programmed death-ligand 1 (PD-L1) expression is the only FDA-approved biomarker for immune checkpoint inhibitors (ICIs) in patients with lung adenocarcinoma,…”
Get full text

Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50 by Gainor, J.F., Rizvi, H., Jimenez Aguilar, E., Skoulidis, F., Yeap, B.Y., Naidoo, J., Khosrowjerdi, S., Mooradian, M., Lydon, C., Illei, P., Zhang, J., Peterson, R., Ricciuti, B., Nishino, M., Zhang, J., Roth, J.A., Grishman, J., Anderson, D., Little, B.P., Carter, B.W., Arbour, K., Sauter, J.L., Mino-Kenudson, M., Heymach, J.V., Digumarthy, S., Shaw, A.T., Awad, M.M., Hellmann, M.D.

“…Immune checkpoint inhibitors (ICIs) are standard therapies for patients with advanced non-small-cell lung cancer (NSCLC) and a programmed death-ligand 1…”
Get full text

New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center by Galateau Salle, F, Le Stang, N, Nicholson, A G, Pissaloux, D, Churg, A, Klebe, S, Roggli, V L, Tazelaar, H D, Vignaud, J M, Attanoos, R, Beasley, M B, Begueret, H, Capron, F, Chirieac, L, Copin, M C, Dacic, S, Danel, C, Foulet-Roge, A, Gibbs, A, Giusiano-Courcambeck, S, Hiroshima, K, Hofman, V, Husain, A N, Kerr, K, Marchevsky, A, Nabeshima, K, Picquenot, J M, Rouquette, I, Sagan, C, Sauter, J L, Thivolet, F, Travis, W D, Tsao, M S, Weynand, B, Damiola, F, Scherpereel, A, Pairon, J C, Lantuejoul, S, Rusch, V, Girard, N

“…The 2015 WHO classification of tumors categorized malignant mesothelioma into epithelioid, biphasic (BMM), and sarcomatoid (SMM) for prognostic relevance and…”
Get more information